These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26637920)

  • 1. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
    Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
    Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Dieras V; Pop S; Berger F; Dujaric ME; Beuzeboc P; Escalup L; Bidard FC; Cottu PH; LE Tourneau C; Piperno-Neumann S; Laurence V; Robain M; Asselain B; Pierga JY
    Anticancer Res; 2017 Mar; 37(3):1403-1407. PubMed ID: 28314310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
    Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
    Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
    Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
    Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
    Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
    Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
    Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
    Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
    Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
    Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
    BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
    Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
    Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
    Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
    Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
    Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
    Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.